Intra-cellular therapies reports second quarter 2023 financial results and raises 2023 caplyta sales guidance

Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022 caplyta q2 2023 net product sales were $110.1 million, compared to $55.1 million for the same period in 2022, representing a 100% increase caplyta's strong prescription uptake continues: q2 2023 caplyta total prescriptions increased 96%, versus the same period in 2022 and 13% sequentially versus q1 2023 2023 caplyta net product sales guidance raised to $445 - $465 million new york, aug. 03, 2023 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, today announced its financial results for the second quarter ended june 30, 2023 and provided a corporate update. “our continued commercial execution resulted in another quarter of solid growth for caplyta.
ITCI Ratings Summary
ITCI Quant Ranking